Dr. Soileau discusses the clinical role of continuous subcutaneous Vyalev (foscarbidopa/foslevodopa) therapy for patients with Parkinson’s disease experiencing motor fluctuations despite optimized oral treatment. He reviews clinical trial data demonstrating

Dr. Irene Malaty, from the University of Florida, discusses how to identify patients who may benefit from Vyalev (foscarbidopa/foslevodopa), highlighting key indicators that a patient is ready to transition beyond

Dr. Jason Aldred, owner of Selkirk Neurology in Spokane, WA, discusses the neuropsychiatric effects and dyskinesia that patients may experience when taking Vyalev (foscarbidopa/foslevodopa).

Dr. Jason Aldred, owner of Selkirk Neurology in Spokane, WA, discusses the safety profile of Vyalev (foscarbidopa/foslevodopa), notably injection site reactions and skin considerations.

Dr. Robert Hauser, from the University of South Florida, provides an overview of Vyalev (foscarbidopa/foslevodopa), highlighting medication administration and mechanism of action, as well as phase 3 trial findings.